Combination Therapies and New Molecular Targets—Presentations from AACR 2021

AACR & ASCO 2021 – Midyear Review
Videos Year in Review
David Spigel, MD
Chief Scientific Officer; Director
Lung Cancer Research Program
Sarah Cannon Research Institute
Nashville, TN
Dr David Spigel reviews potentially practice-changing data on EGFR-TKI combination therapies in NSCLC, new approaches to advanced NSCLC and CNS involvement, and hopeful early data with novel targeted agents.

Related Items

Atezolizumab versus Best Supportive Care After Adjuvant Chemotherapy for Resected NSCLC (IMpower010)
American Association for Cancer Research (AACR)
AACR & ASCO 2021 – Midyear Review
Key Abstracts from ASCO 2021 in NSCLC
By Mark A. Socinski, MD
American Society of Clinical Oncology (ASCO)
AACR & ASCO 2021 – Midyear Review
2021 Midyear Review: Non–Small-Cell Lung Cancer
American Association for Cancer Research (AACR)
AACR & ASCO 2021 – Midyear Review
Combination of Nivolumab and Chemotherapy in Nonmetastatic Resectable NSCLC (CheckMate-816)
American Association for Cancer Research (AACR)
AACR & ASCO 2021 – Midyear Review
Phase 3 Study of Tislelizumab Compared with Docetaxel in Advanced NSCLC (RATIONALE 303)
American Association for Cancer Research (AACR)
AACR & ASCO 2021 – Midyear Review
Acquired Resistance Mutations After Treatment of EGFR-Mutated Metastatic NSCLC with Osimertinib plus Savolitinib (TATTON)
American Association for Cancer Research (AACR)
AACR & ASCO 2021 – Midyear Review
Safety Results of Phase 2 Study of Bintrafusp plus Chemotherapy in Advanced NSCLC (INTR@PID LUNG 024)
American Association for Cancer Research (AACR)
AACR & ASCO 2021 – Midyear Review
Randomized Phase 3 Study of Sintilimab versus Docetaxel in Advanced Squamous NSCLC (ORIENT-3)
American Association for Cancer Research (AACR)
AACR & ASCO 2021 – Midyear Review
Phase 1 Trial of VS-6766, a Dual RAF-MEK Inhibitor, and Defactinib, an FAK Inhibitor
American Association for Cancer Research (AACR)
AACR & ASCO 2021 – Midyear Review
Phase 2 Study of DM-CHOC-PEN in Patients with NSCLC with Central Nervous System Involvement
American Association for Cancer Research (AACR)
AACR & ASCO 2021 – Midyear Review
Conference Coverage Proudly Presented by
American Health & Drug Benefits
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
Personalized Medicine in Oncology

Learn more about our family of publications.

View Our Publications


© Amplity, Inc. All Rights Reserved. Privacy Policy